Core Insights - electroCore, Inc. has announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to investigate the use of gammaCore™ Sapphire, a non-invasive vagus nerve stimulator (nVNS), as an adjunctive treatment for PTSD symptoms [1][2] Study Details - The study titled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder" will be led by Danielle DeSouza MSc, PhD, and aims to assess the safety and effectiveness of gammaCore Sapphire [2] - The primary safety measure will focus on significant adverse events (SAEs) related to nVNS treatment, while the primary efficacy outcome will be the change in the Clinician-Administered PTSD Scale (CAPS-5) total score after a 12-week treatment period [2] - The study will enroll up to 40 subjects aged 18 to 70 diagnosed with PTSD and is expected to last for 10 months [3] Background Information - Acacia Clinics is recognized for its expertise in precision neuromodulation and advanced mental health services, founded in 2018 by Dr. David Carreon and Dr. Nathan Meng [4] - electroCore, Inc. focuses on improving health through innovative non-invasive bioelectronic technologies, with products like gammaCore® and Quell® targeting chronic pain syndromes [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Date of Report (date of earliest event reported): January 20, 2026 electroCore, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 001-38538 20-3454976 (Commission File Number) (I.R.S. Employer Identification Number) 200 Forge Way, Suite 205 Rockaway, NJ 07866 (Address of principal executive offices and zip code) CURRENT REPORT Pursuant to Section ...

Core Insights - electroCore, Inc. anticipates record revenue for full year 2025 of approximately $31.8 - $32.0 million, representing a growth of about 26% compared to 2024 revenue of $25.2 million [2][7] - For the fourth quarter of 2025, the company expects revenue to be approximately $9.0 - $9.2 million, indicating a growth of around 30% over the fourth quarter of 2024 [2][7] - The company's total cash position at the end of 2025 is approximately $11.6 million, down from approximately $13.2 million as of September 30, 2025 [3][7] Financial Guidance - Full year 2025 revenue is projected to be between $31.8 million and $32.0 million, marking a 26% increase from 2024 [2][7] - Fourth quarter 2025 revenue is expected to be between $9.0 million and $9.2 million, reflecting a 30% increase from the same quarter in 2024 [2][7] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, which address chronic pain syndromes [4]

Company Overview - electroCore is a publicly traded neuromodulation company listed on NASDAQ under the symbol ECOR, focusing on non-invasive vagus nerve stimulation devices [3] - The company was founded in 2006 and has developed into a multi-indication business with 7 FDA authorizations for headache treatments [5] Product and Service Channels - The company operates across three main channels: prescription medical devices for headache and migraine, the Truvaga direct-to-consumer wellness brand, and a specialized military and government division featuring the ruggedized TAC-STIM product [4] - The nVNS platform delivers a two-minute therapy session aimed at rebalancing the autonomic nervous system [3] Market and Clientele - electroCore serves major customers including the U.S. Department of Veterans Affairs and the U.K.'s National Health Service, indicating a strong foothold in both governmental and healthcare sectors [5]

Core Insights - electroCore, Inc. announced the publication of a peer-reviewed paper demonstrating the effectiveness of its TAC-STIM™ device in enhancing mood, task performance, and learning in high-stress military training environments [1][2] Study Findings - The study involved 70 active-duty Air Force trainees, who were randomly assigned to receive either tVNS or a sham device during intensive Military Qualification Training [8] - tVNS users reported significantly reduced stress and distress, greater energy, and perceived skill improvements compared to the control group, with p-values indicating statistical significance (p<0.001 for distress, p=0.020 for perceived ability, p=0.002 for energy) [8] - Objective performance gains were observed in intelligence product quality and mission task execution, with tVNS users excelling in real-time operational scenarios [8] Product Positioning - TAC-STIM is positioned as a neuroenhancement tool specifically designed for defense and security applications, with potential for consumer wellness, workplace productivity, and educational markets [5] - The technology aligns with the growing demand for cognitive augmentation tools in civilian domains, including executive training, sports, and healthcare [5] Company Overview - electroCore, Inc. focuses on improving health and quality of life through innovative non-invasive bioelectronic technologies, with leading products including gammaCore and Quell for chronic pain treatment [6] - The company also commercializes handheld products like Truvaga™ and TAC-STIM for general wellness and human performance [6]

Core Insights - electroCore, Inc. is participating in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York [1] - The company will host one-on-one meetings throughout the day for investors [1][2] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device for chronic pain, and Quell Fibromyalgia [3] - Additionally, electroCore offers handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Points - Ecora Resources PLC announced share acquisitions by its CEO Marc Bishop Lafleche and CFO Kevin Flynn, indicating confidence in the company's future performance [1][2][4]. Summary by Sections Share Acquisitions - On November 4, 2025, CEO Marc Bishop Lafleche acquired 32,000 ordinary shares at an average price of £0.931 per share [2][4]. - On November 5, 2025, CFO Kevin Flynn acquired 21,175 shares at an average price of £0.954 per share [2][5]. Regulatory Compliance - The transactions were reported in accordance with Article 19 of the UK Market Abuse Regulation, ensuring transparency in director dealings [3][4]. Company Information - Ecora Resources PLC is listed on the London Stock Exchange and the Toronto Stock Exchange, with the identification code GB0006449366 for its ordinary shares [4][5].

Core Points - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their disabling for full content access [1]

分组1 - electroCore, Inc. reported a quarterly loss of $0.4 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, and compared to a loss of $0.31 per share a year ago, indicating an earnings surprise of -11.11% [1] - The company posted revenues of $8.69 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.69%, and showing an increase from $6.55 million in the same quarter last year [2] - electroCore shares have declined approximately 69.5% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $8.89 million, and for the current fiscal year, it is -$1.59 on revenues of $30.84 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 40% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Financial Data and Key Metrics Changes - In Q3 2025, revenue reached a record $8.7 million, up 33% year over year and 18% sequentially [17] - Gross margins improved to 86%, up from 84% in the previous year [17] - GAAP net loss was $3.4 million, or a loss of $0.40 per share, compared to a net loss of $2.5 million, or a loss of $0.31 per share in Q3 2024 [28] - Cash balance as of September 30, 2025, was approximately $13.2 million, compared to $12.2 million at the end of 2024 [29] Business Line Data and Key Metrics Changes - Prescription device revenue grew 19% year over year to $6.8 million, driven by gammaCore and Quell sales in the VA hospital system [17] - Health and wellness product revenue reached $1.9 million, a 54% increase sequentially and 121% year on year [18] - Truvaga revenue grew 18% sequentially and 79% year on year, excluding a one-time $500,000 order for a clinical trial [19] Market Data and Key Metrics Changes - As of September 30, 2025, 195 VA hospital facilities purchased prescription gammaCore products, up from 166 a year ago [17] - The VA hospital system remains the largest customer, with significant growth opportunities identified in the fibromyalgia patient segment [18] Company Strategy and Development Direction - The company is focusing on three strategic pivots: the Neurometrics acquisition, strengthening the VA channel, and developing the wellness division [9][10][11] - The acquisition of Neurometrics has exceeded revenue expectations and is integrated into the VA hospital channel [23] - The company aims to broaden its product range and diversify revenue streams to enhance long-term shareholder value [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in prioritizing growth over immediate profitability, with a revised timeline for achieving positive adjusted EBITDA in the second half of 2026 [22] - The company is navigating external macroeconomic challenges while maintaining a focus on expanding its market presence [11][12] Other Important Information - The company is facing a patent infringement dispute with a European company, which is currently in litigation [51] - A royalty-based arrangement has been established for commercialization in China, with no capital investment required from the company [13][43] Q&A Session Summary Question: Can you remind us what channels Neurometrics was selling into before the acquisition? - The prescription Quell for fibromyalgia was sold in four or five VA hospitals off contract through open market access prior to the acquisition [36] Question: Can you give us any further color on the $500,000 Truvaga sale for a clinical trial? - It's one clinical trial being run in long COVID subjects, and details are limited as it is investigator-initiated [36] Question: Talk about the next-gen mobile app that you're working on. - The next update of the app will be Truvaga Plus only and will not be set up to work with gammaCore or Quell [37] Question: What is being done to combat the copycat marketing vagus nerve stimulation devices? - The company is in litigation with a European company for patent infringement and is focusing on winning the case [51] Question: How meaningful is the market opportunity in China? - The Chinese investor plans to commercialize the technology in China as a prescription medical device, with royalties paid to the company [43]